Table 3. Characteristic and results of univariate analysis of 290 NSCLC patients with BM.
| Variables (cases) | 1-year survival | 2-year survival | 3-year survival | MST | Log-rank χ2 | P |
|---|---|---|---|---|---|---|
| Gender | 1.040 | 0.308 | ||||
| Male (195) | 53.9 | 28.0 | 12.2 | 13 (10.92-15.08) | ||
| Female (95) | 60.4 | 28.6 | 11.2 | 16 (13.37-18.63) | ||
| Age | 0.667 | 0.454 | ||||
| ≤65 y (227) | 56.7 | 29.5 | 11.0 | 15 (12.77-17.23) | ||
| >65 y (63) | 53.5 | 23.8 | 17.0 | 13 (10.75-15.25) | ||
| Histology subtype | 20.668 | 0.000 | ||||
| Adenocarcinoma (224) | 58.8 | 31.5 | 13.7 | 16 (13.71-18.29) | ||
| No-adenocarcinoma (66) | 45.6 | 16.7 | 6.0 | 10 (5.50-13.44) | ||
| KPS | 19.763 | 0.000 | ||||
| <70 (160) | 47.3 | 20.2 | 4.2 | 12 (10.85-13.15) | ||
| ≥70 (130) | 66.7 | 38.2 | 21.0 | 21 (17.70-25.30) | ||
| Surgery of lung cancer | 4.839 | 0.028 | ||||
| Yes (60) | 61.7 | 38.2 | 24.0 | 19 (12.27-25.73) | ||
| No (230) | 54.5 | 25.6 | 8.8 | 14 (12.28-15.72) | ||
| Extracranial status | 0.974 | 0.615 | ||||
| Bone only (77) | 53.4 | 23.7 | 13.8 | 16 (11.21-20.78) | ||
| Verscial organ (40) | 54.0 | 29.9 | 5.1 | 13 (13.95-18.05) | ||
| No (173) | 57.6 | 30.6 | 12.8 | 14 (12.10-15.89) | ||
| Lung lesion status | 2.481 | 0.117 | ||||
| Controlled (62) | 64.5 | 37.3 | 15.0 | 17 (8.17-25.81) | ||
| Uncontrolled (228) | 53.7 | 25.7 | 11.3 | 14 (12.57-15.83) | ||
| Number of BM | 8.535 | 0.014 | ||||
| 1 (121) | 63.9 | 36.4 | 23.1 | 17 (13.76-20.24) | ||
| 2-3 (34) | 48.0 | 20.9 | 7.0 | 12 (6.69-17.31) | ||
| >3 (135) | 51.0 | 22.9 | 6.3 | 13 (11.23-14.76) | ||
| Previous surgery of BM | 4.953 | 0.026 | ||||
| Yes (12) | 91.7 | 51.3 | 12.8 | 28 (14.13-41.86) | ||
| No (278) | 54.5 | 27.2 | 12.5 | 14 (12.38-15.62) | ||
| Interval of BM | 3.672 | 0.055 | ||||
| Synchronous (192) | 54.4 | 22.2 | 9.2 | 13 (11.17-14.83) | ||
| Metachronous (98) | 59.2 | 38.0 | 16.4 | 16 (10.52-21.48) | ||
| Systemic chemotherapy | 1.219 | 0.270 | ||||
| 0-1 cycle (126) | 52.4 | 26.2 | 13.4 | 13 (11.06-14.94) | ||
| ≥2 cycles (164) | 58.8 | 29.8 | 10.2 | 16 (13.41-18.59) | ||
| Molecular targeted therapy | 20.277 | 0.000 | ||||
| 0 (185) | 46.7 | 26.8 | 11.2 | 12 (9.95-14.05) | ||
| 1-3 months (35) | 48.1 | 11.8 | 0 | 12 (9.23-14.78) | ||
| >3 months (70) | 84.3 | 40.9 | 20.5 | 21 (16.78-25.22) | ||
| Brain irradiation arms | 2.645 | 0.450 | ||||
| SRS alone (70) | 51.4 | 26.5 | 7.7 | 13 (10.32-15.68) | ||
| WBRT alone (200) | 57.6 | 29.0 | 12.8 | 15 (12.89-17.12) | ||
| SRS+WBRT (20) | 45.0 | 25.0 | 12.5 | 12 (9.82-14.18) | ||
| RPA class | 63.484 | 0.000 | ||||
| RPA I (32) | 78.1 | 43.5 | 19.3 | 23 (13.81-32.19) | ||
| RPA II (211) | 59.8 | 31.1 | 13.8 | 16 (13.95-18.05) | ||
| RPA III (47) | 23.3 | 4.7 | 0 | 5 (2.83-7.17) | ||
| GPA | 32.728 | 0.000 | ||||
| 0-1 (56) | 37.9 | 8.5 | 0 | 9 (5.50-12.49) | ||
| 1.5-2.5 (169) | 54.7 | 26.3 | 12.6 | 13 (10.97-15.03) | ||
| 3 (43) | 72.1 | 47.4 | 12.1 | 24 (12.89-35.10) | ||
| 3.5-4 (22) | 81.1 | 56.1 | 46.7 | 30 (16.44-43.56) |
WBRT: whole-brain radiotherapy; KPS: Karnofsky performance status; RPA: recursive partitional analysis; GPA: graded prognostic assessment; SRS: stereoradiosurgery; OS: overall survival; MST: Median survival time.